CSHL 2023 Conference on Biology of Cancer: Microenvironment & Metastasis

癌症生物学：微环境与转移 冷泉港，纽约 2023年9月19日至23日 摘要 癌症现在被认为是一种异常器官，在这种情况下，多种类型的细胞在 癌症的发生和转移进展。在确定身份方面取得了巨大进展 肿瘤细胞的遗传、表观遗传和代谢变化及不同细胞的特征 组成肿瘤的细胞类型，了解这些细胞类型相互作用的机制 共同开发成像肿瘤变化的方法并探索治疗方法 考虑到非恶性细胞的机会。因此，出现了一种 需要一种综合的方法来控制癌症。然而，大多数癌症会议都是 组织集中在肿瘤生物学的许多方面的一个或两个方面。这个 提议的会议采用综合方法来创建平台并汇聚世界 癌症生物学、遗传学、表观遗传学、新陈代谢、信号转导、 免疫学、诊断学和治疗学，讨论最新发现并促进对话 旨在解决阻碍临床持久反应的主要问题。我们相信 这种综合方法将引发跨学科的讨论和互动 边界，并找到新的方法来开发和提供新的治疗策略来控制 癌症。 这次两年一度的会议的第七次重演将吸引来自学术实验室的参与者， 研究机构和生物技术/制药行业，并将包括该领域的领导者， 资深研究员、初级教员、博士后研究员、研究生和企业 科学家。为了确保展示最尖端的结果，许多演讲者将 根据提交给会议协调员和届会的摘要质量进行选择 在会议前几个月担任主席。我们的重点将放在未发表的结果上。至 为了最大限度地扩大参与，已作出努力将杰出的女科学家包括在内 来自国外的科学家担任会议主席和特邀演讲者。每节课都会是 由组织者选出的两位该领域的顶尖科学家担任主席。口头陈述将 从各届会议主席与组织者协商后提交的摘要中选出。 选定的演讲者将包括研究生、博士后研究员和初级教员Aiming 最大限度地吸纳年轻调查人员。此外，促进对下一步的认可 一代科学家，一个最新的会议将与被邀请的早期职业生涯聚集在一起 研究人员将讨论癌症生物学方面令人兴奋的进展。特别重要的是这两个 海报会议和小组讨论。海报会议为许多人提供了一个机会 与会者在有利于非正式讨论的气氛中介绍他们的工作 小组讨论使思想领袖和与会者就一个高度辩论的话题展开讨论 个性化癌症药物在提高癌症治疗中的作用。这次会议 将是中等规模的，我们预计大约有300人参加，其中绝大多数 将展示一张海报或演讲。

Biology of Cancer: Microenvironment & Metastasis Cold Spring Harbor, New York September 19 – 23, 2023 ABSTRACT Cancer is now recognized as an abnormal organ where multiple cell types cooperate during cancer initiation and metastatic progression. Enormous progress has been made on identifying genetic, epigenetic and metabolic alterations in tumor cells and characterizing the different cell types composing a tumor, understanding the mechanisms by which these cell types interact with each other, developing ways to image the changes in a tumor and exploring therapeutic opportunities that take into account the non-malignant cells. Thus, there is an emergence of a need for an integrative approach for controlling cancer. However, most cancer meetings are organized to focus on one or two aspects of the many aspects of the biology of tumor. The proposed meeting takes an integrative approach to create a platform and bring together world leaders in different aspects of cancer biology, genetics, epigenetics, metabolism, signaling, immunology, diagnostics, and therapeutics to discuss the latest findings and promote dialogue aimed at solving the chief problems that prevent durable responses in the clinic. We believe that such an integrative approach will trigger discussions and interactions that cross the disciplinary borders and find new ways to develop and deliver novel therapeutic strategies for controlling cancer. The seventh rendition of this biennial conference will draw participants from academic labs, research institutes and biotech/pharmaceutical industries, and will include leaders in the field, established investigators, junior faculty, postdoctoral fellows, graduate students and corporate scientists. To ensure the presentation of the most cutting edge results many speakers will be chosen based on the quality of abstracts submitted to the meeting coordinators and session chairs several months prior to the meeting. Our emphasis will be on unpublished results. To maximize broad participation, efforts have been made to include outstanding women scientists and scientists from abroad as session chairs and invited speakers. Each session will be chaired by two leading scientists in the field selected by the organizers. Oral presentations will be selected from submitted abstracts by the session chairs in consultation with the organizers. Selected speakers will include graduate students, postdoctoral fellows and junior faculty aiming for maximal inclusion of young investigators. In addition, to promote recognition of the next generation of scientists, a late breaking session will be assembled with invited early career investigators to discuss exciting advances in cancer biology. Of special importance are the two poster sessions and panel discussion. The poster session provide an opportunity for many participants to present their work in an atmosphere conducive to informal discussion and the panel discussion engages thought leaders and the participants on one highly debated topic on the role played by personalized cancer medicine in improving cancer treatment. The meeting will be of moderate size and we expect about 300 people to attend, the vast majority of whom will be presenting a poster or talk.